News

Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...
Opens in a new tab or window A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ... The patient died after experiencing acute liver ...
A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...
Shares of Sarepta, based in Cambridge, Massachusetts, dropped more than 27% on Tuesday, closing at about $73 per share. Elevidys, which costs $3.2 million for a one-time infusion, was the first gene ...
Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy ... noted that over 800 patients have now been treated with the therapy.
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys ... crossed over to receive Elevidys after initially ...
Patient was a 16-year-old teen, who underwent treatment in Dec First death reported ... acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular ...
WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular ... from an Alabama woman after a record 130 days The House ...
The patient, a young man, suffered acute liver failure after receiving the therapy ... death. Fatalities have also been reported following the launch of Novartis’s Zolgensma, an AAV-delivered ...
Yet on Tuesday, Sarepta shares sank as much as 25% after the company reported the death of a young man from acute liver failure following treatment with its gene therapy. The news was ...
A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment. The company behind the drug, Sarepta ...